BR112016028888A2 - compostos que compreendem o sistema 1,1',2,5'-tetra hidro espiro [indol-3,2'-pirrol]-2,5'-diona como inibidores de interação proteína-proteína p53-mdm2 - Google Patents

compostos que compreendem o sistema 1,1',2,5'-tetra hidro espiro [indol-3,2'-pirrol]-2,5'-diona como inibidores de interação proteína-proteína p53-mdm2

Info

Publication number
BR112016028888A2
BR112016028888A2 BR112016028888A BR112016028888A BR112016028888A2 BR 112016028888 A2 BR112016028888 A2 BR 112016028888A2 BR 112016028888 A BR112016028888 A BR 112016028888A BR 112016028888 A BR112016028888 A BR 112016028888A BR 112016028888 A2 BR112016028888 A2 BR 112016028888A2
Authority
BR
Brazil
Prior art keywords
protein
tetrahydrospiro
mdm2
pyrrol
indol
Prior art date
Application number
BR112016028888A
Other languages
English (en)
Inventor
Burchard Ewa
Kalinowska Iwona
Adriana Jaszczewska Joanna
Wos-Latosi Katarzyna
Feder Marcin
Mazur Maria
Bulkowska Urszula
Lewandowski Wojciech
Original Assignee
Adamed Sp Zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo
Publication of BR112016028888A2 publication Critical patent/BR112016028888A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

expõe-se um composto de espirooxoindol representado pela fórmula selecionada a partir do grupo que consiste da fórmula (ia) e (ib), em que todos os símbolos são tais como definidos na descrição. o composto pode encontrar uso em um método de prevenção e / ou tratamento de enfermidades selecionadas a partir do grupo que consiste de câncer, enfermidades imunológicas, condições inflamatórias, enfermidades alérgicas da pele associadas com proliferação excessiva, e infecções por vírus.
BR112016028888A 2014-06-12 2015-06-11 compostos que compreendem o sistema 1,1',2,5'-tetra hidro espiro [indol-3,2'-pirrol]-2,5'-diona como inibidores de interação proteína-proteína p53-mdm2 BR112016028888A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL40854014 2014-06-12
PCT/IB2015/054425 WO2015189799A1 (en) 2014-06-12 2015-06-11 Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction

Publications (1)

Publication Number Publication Date
BR112016028888A2 true BR112016028888A2 (pt) 2017-08-22

Family

ID=54832985

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028888A BR112016028888A2 (pt) 2014-06-12 2015-06-11 compostos que compreendem o sistema 1,1',2,5'-tetra hidro espiro [indol-3,2'-pirrol]-2,5'-diona como inibidores de interação proteína-proteína p53-mdm2

Country Status (13)

Country Link
US (1) US20170129903A1 (pt)
EP (1) EP3154982B1 (pt)
JP (1) JP2017517555A (pt)
KR (1) KR20170012559A (pt)
CN (1) CN106795168A (pt)
AU (1) AU2015273106A1 (pt)
BR (1) BR112016028888A2 (pt)
CA (1) CA2947134A1 (pt)
EA (1) EA030564B9 (pt)
IL (1) IL248839A0 (pt)
MX (1) MX2016016363A (pt)
WO (1) WO2015189799A1 (pt)
ZA (1) ZA201700110B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
EP3558302A4 (en) 2016-12-21 2020-07-15 Board of Regents of the University of Nebraska DIMERS OF COVALENTS NFKB INHIBITORS
EA202091583A1 (ru) * 2017-12-29 2020-10-08 Ган Энд Ли Фармасьютикалз Соединения, которые могут применяться в качестве ингибитора опухоли, способ их получения и их применение
EP3511334A1 (en) 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
KR102039696B1 (ko) 2018-04-23 2019-11-04 충남대학교산학협력단 세포내 결핵균 제어를 위한 p53 발현 조절 가능한 조성물 (K279-1558) 또는 방법
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN114057756B (zh) * 2021-12-10 2022-12-09 山东第一医科大学(山东省医学科学院) 一种抗肿瘤活性的吡咯烷基螺氧化吲哚类化合物及其合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE408593T1 (de) 2001-05-03 2008-10-15 Galileo Lab Inc Pyruvatderivate
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
WO2007114338A1 (ja) 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US20110294842A9 (en) 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
US8217044B2 (en) * 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
PL2684880T3 (pl) 2011-03-10 2018-07-31 Daiichi Sankyo Company, Limited Pochodna dispiropirolidyny
SG194873A1 (en) * 2011-05-11 2013-12-30 Sanofi Sa Spiro-oxindole mdm2 antagonists

Also Published As

Publication number Publication date
IL248839A0 (en) 2017-01-31
ZA201700110B (en) 2018-04-25
EA030564B9 (ru) 2019-02-28
CA2947134A1 (en) 2015-12-17
US20170129903A1 (en) 2017-05-11
KR20170012559A (ko) 2017-02-02
EA030564B1 (ru) 2018-08-31
AU2015273106A1 (en) 2016-11-17
CN106795168A (zh) 2017-05-31
WO2015189799A1 (en) 2015-12-17
EA201692550A1 (ru) 2017-07-31
EP3154982B1 (en) 2018-05-02
JP2017517555A (ja) 2017-06-29
MX2016016363A (es) 2017-04-06
EP3154982A1 (en) 2017-04-19

Similar Documents

Publication Publication Date Title
BR112016028888A2 (pt) compostos que compreendem o sistema 1,1',2,5'-tetra hidro espiro [indol-3,2'-pirrol]-2,5'-diona como inibidores de interação proteína-proteína p53-mdm2
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
CL2016002735A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EA201800367A1 (ru) Способы лечения болезни хантингтона
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
EA201401281A1 (ru) D-аминокислотные химические соединения для лечения заболеваний печени
CR20150510A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
EA202090371A1 (ru) 1H-ПИРРОЛО[2,3-c]ПИРИДИН-7(6H)-ОНЫ И ПИРАЗОЛО[3,4-c]ПИРИДИН-7(6H)-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕЛКОВ BET
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
WO2015048547A3 (en) Methods for using and biomarkers for ampk-activating compounds
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201591740A1 (ru) Вирусы болезни ньюкасла и их применение
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112015017519A2 (pt) compostos e métodos para o tratamento de infecções bacterianas
EA201300871A1 (ru) ПРОИЗВОДНЫЕ (1,2,4)ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ
BR112017002369A2 (pt) derivados de diazepana e usos dos mesmos
MX2015015782A (es) Derivados de nucleosido 4'-fluoro-2'-metil sustituido.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
ECSP17010481A (es) Novedosas pirimidinas 2,5-sustituidas
MX2019005097A (es) Composiciones y metodos para tratar la enfermedad del enverdecimiento de los citricos.
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]